Allogene Therapeutics: Funding, Investors & Team (Sep 2026)
Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Allogene Therapeutics has raised $200M across 1 funding round on record, the most recent an undisclosed round of $200M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Allogene Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Allogene Therapeutics Funding Rounds
Allogene Therapeutics Founders and Leadership Team
Contact details for the Allogene Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Allogene Therapeutics Funding Compared to Other Biotechnology Startups
Allogene Therapeutics' latest round of $200M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Allogene Therapeutics in Biotechnology and South San Francisco
Companies Similar to Allogene Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Allogene Therapeutics Funding FAQs
What does Allogene Therapeutics do?
Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
How much funding has Allogene Therapeutics raised?
Allogene Therapeutics has raised $200M across 1 round on record. The most recent is an undisclosed round of $200M announced in Apr 2026.
When did Allogene Therapeutics last raise funding?
Allogene Therapeutics' most recent funding round on record is an undisclosed round of $200M, announced in Apr 2026.
Who founded Allogene Therapeutics?
FundedIQ lists David Chang (Founder) at Allogene Therapeutics.
Where is Allogene Therapeutics headquartered?
Allogene Therapeutics is based in South San Francisco, California, United States.
How many employees does Allogene Therapeutics have?
Allogene Therapeutics is in the 101-250 employee band.
How does Allogene Therapeutics' funding compare to other Biotechnology startups?
Allogene Therapeutics' latest round of $200M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Allogene Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Allogene Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.